Migsun (Naproxen Sodium, Sumatriptan Succinate)

Migsun combines an NSAID and a triptan to address the migraine pathway and provides rapid relief during an attack.

• Migraine without aura: aborts headache pain and associated symptoms within hours.
• Migraine with aura: terminates the headache phase after aura resolution.
• Acute migraine attack: reduces nausea, photophobia and phonophobia associated with the episode.

• Naproxen sodium inhibits cyclooxygenase‑1 and ‑2 enzymes, decreasing prostaglandin synthesis and reducing inflammation. Sumatriptan succinate selectively activates 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings, causing vasoconstriction and blocking release of vasoactive neuropeptides. By targeting both inflammatory mediators and vascular tone, the formulation offers a synergistic approach to terminate the migraine cascade.

Migsun may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild stomach upset often occurring shortly after dosing.
• Dizziness: transient light‑headedness that usually resolves without intervention.
• Dry mouth: reduced salivation leading to throat discomfort.
• Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects

• Chest tightness or pressure: may indicate coronary vasospasm and requires immediate medical attention.
• Serotonin syndrome: rare but serious condition with agitation, hyperthermia, and muscle rigidity.
• Gastrointestinal bleeding: severe stomach or intestinal bleeding that can be life‑threatening.

Before prescribing Migsun, clinicians should evaluate several safety considerations to minimize risk.

• Cardiovascular assessment: review history of ischemic heart disease, uncontrolled hypertension or cerebrovascular disorders.
• Bleeding risk: avoid in patients with active gastrointestinal ulcers or concurrent anticoagulant therapy.
• Hepatic or renal impairment: adjust use cautiously in moderate to severe liver or kidney dysfunction.
• Serotonergic agents: assess concomitant use of SSRIs, SNRIs or MAO inhibitors to prevent serotonin syndrome.
• Pregnancy and lactation: consider potential risks and discuss alternatives with women of childbearing potential.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Migsun can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use may precipitate severe hypertension or serotonin syndrome.
• SSRIs, SNRIs, or other serotonergic drugs: increase risk of serotonin syndrome when combined with sumatriptan.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise sumatriptan plasma levels, heightening adverse effects.

Moderate Interactions (Monitor Closely)

• Anticoagulants or antiplatelet agents: naproxen may enhance bleeding risk.
• Other NSAIDs: combined use can increase gastrointestinal toxicity.
• Antihypertensive agents: sumatriptan may attenuate the effect of blood pressure medications.